ORM-12741

DRUG10 trials

Sponsors

Orion Corporation, Orion Pharma, University of Cape Town

Conditions

Alzheimer's DiseaseHealthyHealthy Male VolunteersHealthy VolunteerHealthy Volunteers

Early Phase 1

Early Phase I Microdosing Study of ORM-14540 and ORM-12741

CompletedNCT00831077

Orion Corporation, Orion PharmaHealthy

Start: 2009-01-31End: 2009-04-30Updated: 2009-10-08

Phase 1

Safety and Tolerability Study With Single Ascending Doses of ORM-12741

CompletedNCT00693316

Orion Corporation, Orion PharmaHealthy

Start: 2008-07-31End: 2009-10-31Updated: 2010-02-11

Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741

CompletedNCT00792493

Orion Corporation, Orion PharmaHealthy

Start: 2008-12-31End: 2009-09-30Updated: 2009-09-24

Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741

CompletedNCT00817544

Orion Corporation, Orion PharmaHealthy Male Volunteers

Start: 2009-01-31End: 2009-03-31Target: 6Updated: 2009-03-16

Pharmacokinetic Study of ORM-12741 in Healthy Volunteers

CompletedNCT00818740

Orion Corporation, Orion PharmaHealthy Volunteers

Start: 2009-01-31End: 2009-06-30Updated: 2009-10-08

A PET Study With ORM-12741

CompletedNCT00829907

Orion Corporation, Orion PharmaHealthy

Start: 2009-01-31End: 2009-06-30Updated: 2009-11-25

Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741

CompletedNCT01068028

Orion Corporation, Orion PharmaHealthy

Start: 2010-02-28End: 2010-07-31Updated: 2010-08-16

Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers

CompletedNCT03440021

University of Cape TownHealthy Volunteer

Start: 2018-03-26End: 2018-12-06Updated: 2019-01-10

Phase 2

Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease

CompletedNCT01324518

Orion Corporation, Orion PharmaAlzheimer's Disease

Start: 2011-04-30End: 2012-10-31Updated: 2021-04-28

Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease

CompletedNCT02471196

Orion Corporation, Orion PharmaAlzheimer's Disease

Start: 2015-08-14End: 2017-12-04Updated: 2018-02-15

Related Papers

Application of the PET ligand [<sup>11</sup>C]ORM-13070 to examine receptor occupancy by the α<sub>2C</sub>-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain.

2020-12-094 citations